DNA Methylation Analysis to Unravel Altered Genetic Pathways Underlying Early Onset and Late Onset Neonatal Sepsis. A Pilot Study

Sheila Lorente-Pozo 1,2†, Paula Navarrete 3†, María José Garzón 3, Inmaculada Lara-Cantón 1,2, Jesús Beltrán-García 4,5, Rebeca Osca-Verdegal 4,5, Salvador Mena-Mollá 2,5, Eva García-López 3, Máximo Vento 1,2, Federico V. Pallardó 3,4,5 and José Luis García-Giménez 3,4,5*

1 Neonatal Research Group, Health Research Institute La Fe, Valencia, Spain, 2 Division of Neonatology, University and Polytechnic Hospital La Fe, Valencia, Spain, 3 EpiDisease S.L. (Spin-off from the CIBER-ISCIII), Parc Científic de la Universitat de València, Paterna, Spain, 4 Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Valencia, Spain, 5 Department Fisiología, Facultad de Medicina y Odontología, Universidad de Valencia-InCLIVA, Valencia, Spain

Background: Neonatal sepsis is a systemic condition widely affecting preterm infants and characterized by pro-inflammatory and anti-inflammatory responses. However, its pathophysiology is not yet fully understood. Epigenetics regulates the immune system, and its alteration leads to the impaired immune response underlying sepsis. DNA methylation may contribute to sepsis-induced immunosuppression which, if persistent, will cause long-term adverse effects in neonates.

Objective: To analyze the methylome of preterm infants in order to determine whether there are DNA methylation marks that may shed light on the pathophysiology of neonatal sepsis.

Design: Prospective observational cohort study performed in the neonatal intensive care unit (NICU) of a tertiary care center.

Patients: Eligible infants were premature ≤32 weeks admitted to the NICU with clinical suspicion of sepsis. The methylome analysis was performed in DNA from blood using Infinium Human Methylation EPIC microarrays to uncover methylation marks.

Results: Methylation differential analysis revealed an alteration of methylation levels in genomic regions involved in inflammatory pathways which participate in both the innate and the adaptive immune response. Moreover, differences between early and late onset sepsis as compared to normal controls were assessed.

Conclusions: DNA methylation marks can serve as a biomarker for neonatal sepsis and even contribute to differentiating between early and late onset sepsis.

Keywords: neonatology and pediatric intensive care, DNA methylation, sepsis, inflammation, immunosuppression
INTRODUCTION

Neonatal sepsis is a leading cause of mortality and morbidity in the neonatal period, especially for preterm infants (1). Sepsis is defined as a dysregulated host response caused by infection which can trigger a life-threatening organ failure (2). However, neonatal sepsis lacks a consensus definition (3) and therefore a full understanding of the underlying mechanisms which are functionally distinct in children and adults is needed (3). The neonatal immune response depends mainly on the innate immune system, which is underdeveloped (4, 5); along with a predominant hypo-inflammatory response, this can lead to immunosuppression (6).

Diagnosis and prognosis of neonatal sepsis is a challenge because clinical signs and symptoms are often non-specific. In addition, the result of the blood culture for confirmation of the diagnosis is frequently delayed or provides no results (7). Moreover, given the effects of sepsis in preterm infants on long-term growth and development, efforts to reduce the rates of infection in the neonatal intensive care unit (NICU) are among the most important interventions in neonatal care (8). According to the onset of age, neonatal sepsis is divided into early-onset sepsis (EOS) and late-onset sepsis (LOS). EOS is defined as the onset of features of sepsis that appear within 72 h of life caused by microorganisms acquired from the mother’s genital tract during delivery (9–11). In contrast, LOS is defined as onset of features of sepsis appear after 72 h of life due to nosocomial infections acquired during hospitalization (11, 12).

In this context, there is a growing interest in understanding the role of epigenetics in the maturation of the immune system during early life (13) and particularly in sepsis (14, 15). Epigenetics encompasses all the mechanisms that control the gene expression pattern without altering the DNA sequence itself (16–18). Changes in the epigenome can impair immune response to infections (14, 15), suggesting that the study of epigenetic traits through epigenome-wide association studies (EWAS) can improve our understanding of sepsis onset and progression, and even short- and long-term consequences of the disease (19).

In particular, DNA methylation (DNAm) is an important regulator of the immune system (20), maintaining fine-tuned immunological mechanisms needed for an adequate host defense. One of the major consequences of neonatal sepsis is long-term persistence of immunosuppression related to epigenetic dysregulation (6), leading to subsequent infections and increased risk of mortality (15, 21). Importantly, DNAm may drive sepsis-induced immunosuppression through the epigenetic reprogramming of hematopoietic progenitor cells (19). In line with this, although DNAm changes in adult sepsis have been described in some studies (22, 23), information on neonatal sepsis is lacking (24).

We aimed to detect changes in DNAm signatures in preterm neonates that might provide an insight into molecular events driving neonatal sepsis. Consequently, this could contribute to the identification of new biomarkers for the diagnosis and prognosis of neonatal sepsis.

MATERIALS AND METHODS

Experimental Design

The study was performed in the NICU of the Hospital Universitario y Politécnico La Fe (Valencia, Spain). Samples from neonates were obtained from the study approved by the Ethics Committee with registration number 2017/0470. Parents of all the patients signed the informed consent. This is a prospective cohort study that included preterm neonates born at ≤32 weeks of gestation age. Inclusion and exclusion criteria for the study are shown in Supplementary Table 1.

Samples from 23 preterm infants were collected coincident with clinical suspicion of EOS or LOS. Preterm neonates with similar gestational and postnatal ages and perinatal characteristics but free of infection and without suspicion of sepsis acted as controls. EOS and LOS were diagnosed by attending staff neonotologists in the NICU. Patients who met EOS and LOS criteria were included in the study (21, 22). Six patients had confirmed EOS, nine patients confirmed LOS, and two patients suffered both types. Six non-septic preterm neonates were used as controls (Table 1). Although a positive blood culture is the golden standard for the diagnosis of sepsis including EOS and LOS, often blood culture renders negative due to the low blood volume available and contamination by peripheral colonizing bacteria. Therefore, in clinical neonatology there is a distinction between “culture positive sepsis” and “clinical sepsis” (Table 2). Culture positive sepsis is characterized by a positive bacterial growth in two blood samples taken under stringent aseptic conditions and is treated with specific antibiotics provided by the antibiogram. Clinical sepsis is characterized by the presence of evident of clinical signs that can be or not accompanied by changes in acute phase reactant biomarkers such as CRP, IL-6, or PCT, and or positive peripheral smears and is treated with an empirical combination of antibiotics according to the bacterial eco-system of the NICU. These criteria were not mutually exclusive, and some patients were identified as suffering from both EOS and LOS, being the blood sample taken for analysis after the second sepsis episode.

Blood Sampling and DNA Extraction

Blood (0.5 mL) was sampled from a peripheral vein or central catheter using a heparinized syringe. Blood was centrifuged (1,500 × g for 10 min) at 4°C to separate plasma from the cell pellet. Cell fractions were stored at −80°C until processing. Total DNA was isolated from the cell pellet with All-In-One DNA/RNA Miniprep Kit (BS88203, Bio Basic Canada Inc., Canada) following the manufacturer’s instructions. Concentration and purity of DNA was determined with the fluorometric method (Quant-iT PicoGreen dsDNA Assay, Life Technologies, Carlsbad, CA, USA).

DNA Methylation Profiling Using Illumina EPIC 850K Array

The measurement of genome-wide methylation on the 23 samples was performed by means of the Infinium Human DNA
Methylation EPIC 850K arrays (Illumina Inc, San Diego, CAL, USA) following the manufacturer's instructions.

Bioinformatic Analysis
The minfi R-package (27) was used to process and normalize the arrays (28, 29). The identification of differentially methylated CpGs (DMCs) was performed using limma (30) using an FDR cutoff of 0.05, which is the expected proportion of errors and controls for a low proportion of false positives (38). With the aim of discovering differentially methylated regions (DMRs), we employed two complementary bioinformatic tools: DMRcate (34) and mCSEA (39) R-packages. We performed the DNAm differential analysis between the groups of the study. Finally, we performed the overlap of both DMR sets.

DMRs were functionally enriched in both gene ontology (GO) terms and KEGG pathways by means of an over-representation analysis (ORA) using the clusterProfiler R-package (40). The selected FDR threshold was 0.05. Furthermore, the top 1,000 DMCs were analyzed for cell-type enrichment using eFORGE (35), which determines the cell type-specific regulatory component of a set of EWAS-identified differentially methylated positions to identify disease-relevant cell types in a specific disease.

Statistical Analysis
Quantitative variables were analyzed for normality using the Kolmogorov-Smirnov test, and an ordinary one-way ANOVA was performed for multiple comparisons using Tukey's test. Furthermore, qualitative variables were analyzed using Fisher's exact test.

RESULTS
Neonatal Characteristics and Microbiological Data
Twenty-three preterm infants (<32 weeks of gestation age) were included. Out of these, 17 were diagnosed of neonatal sepsis cases and 6 pre-term neonates were selected as non-septic controls. Subjects' characteristics are shown in Table 1 and the criteria for “culture positive sepsis” and “clinical sepsis,” as well as inflammatory biomarkers, are shown in Table 2. Hence, 9 subjects developed LOS, 6 subjects developed EOS, 2 subjects

| Variables | LOS (N = 9) | EOS (N = 6) | LOS and EOS (N = 2) | CRL (N = 6) | p-value | p-value | p-value | p-value |
|-----------|-------------|-------------|---------------------|-------------|---------|---------|---------|---------|
| Gestational age (weeks) (median; 5–95% CI) | 26 (25–29) | 27 (25–30) | 25 (25) | 29.5 (25–30) | *0.02a | *0.04a | 0.40a |
| Birth weight (g) (mean ± SD) | 797.8 ± 228.7 | 1082.5 ± 338.2 | 845 ± 49.5 | 1253 ± 261 | *0.02a | 0.68a | 0.26a | 0.21a |
| Apgar score 1 min (median; 5–95% CI) | 7 (4–8) | 7 (4–9) | 5 (4–6) | 8.5 (6–10) | 0.27a | 0.59a | 0.22a | 0.97a |
| Apgar score 5 min (median; 5–95% CI) | 9 (6, 9) | 8.5 (6–10) | 7.5 (7, 8) | 9 (8–10) | 0.69a | 0.70a | 0.25a | >0.99a |
| Male sex (n, %) | 7 (77.8) | 4 (66.7) | 2 (100) | 3 (31) | 0.33b | >0.99b | 0.46b | >0.99b |
| Type of delivery: vaginal/cesarean (n, %) | 2 (77.8) | 0 (0) | 2 (100) | 1 (5) | >0.99b | >0.99b | 0.11b | 0.49b |
| Twin pregnancy (n, %) | 4 (44.4) | 3 (31) | 2 (100) | 3 (31) | >0.99b | >0.99b | 0.46b | >0.99b |
| Antibiotic therapy to mother (n, %) | 9 (100) | 6 (100) | 2 (100) | 6 (100) | >0.99b | >0.99b | >0.99b | >0.99b |
| Weight at sample collection (g) (mean ± SD) | 1087 ± 270.2 | 1007 ± 266.4 | 1223 ± 661.1 | 1205 ± 243.4 | 0.87a | 0.66a | >0.99a | 0.95a |

α Full course of antenatal steroids: 12-mg doses of betamethasone given intramuscularly 24 h apart or four 6-mg doses of dexamethasone administered intramuscularly every 12 h.
β Chorioamnionitis or intra-amniotic infection was defined as an acute inflammation of the membranes and chorion of the placenta with clinical, histologic, or microbiological findings.
* Tukey’s multiple comparisons test.
* Fisher’s exact test.
* p-value < 0.05 was considered statistically significant.
### Differential Methylation Profiles Between Neonatal Sepsis Subtypes and Control Subjects

Principal component analysis (PCA) of the processed data showed a slight separation between septic and control samples, with some overlap. Regarding subtypes, LOS samples showed greater separation from controls than did EOS (Figure 1A).

The differential methylation analysis between septic and control neonates showed 77,380 differentially methylated CpGs (DMCs). The top 1,000 DMCs were plotted in a heatmap showing a similar methylation pattern in both clinical groups, EOS and LOS (Figure 1B). The eFORGE analysis of the top 1,000 DMCs revealed enrichment in blood enhancers, particularly primary hematopoietic stem cells (Figure 1C).

To identify DMRs, we used the mCSEA approach, testing 1,051 promoters and 119 genes with differential methylation levels in the neonatal sepsis condition vs. controls. In particular, we found 437 hypomethylated promoters, 26 of which exhibited a beta-value difference >10% (including the promoters for EGOT, IL10, CPT1B, PILRA, ELANE, TREM1, PRTN3, MIR145, S100A8, CSTA, MS4A3, ATP8B4, CPT1B, CMYA5, LRG1, and CD300LB) and 614 hypermethylated promoters, 6 of which exhibited a beta-value difference >10% for CD3G, CD3D, LTA, TXK, UBASH3A,

---

**TABLE 2** | Summary of microbiological, clinical, and analytical results in patients with early and late onset sepsis.

| Patient identification | Blood culture results | Clinical signs | Dab suspected sepsis | Lactic acid | CRP | IL6 | WBC count (per mm³) | Neutrophils (per mm³) |
|------------------------|-----------------------|----------------|----------------------|------------|-----|-----|---------------------|----------------------|
| **Late onset sepsis**  |                       |                |                      |            |     |     |                     |                      |
| Patient 1 (5)          | Staphylococcus epidermidis | Present | 7                   | 2.4        | 75.9| –   | 41,250              | 38,130               |
| Patient 2 (7)          | S. epidermidis         | Present | 19                  | 1.5        | 31.9| –   | 16,840              | 8,450                |
| Patient 3 (19)         | S. epidermidis         | Present | 25                  | 3.6        | 64.6| –   | 35,510              | 19,630               |
| Patient 4 (20)         | S. epidermidis         | Present | 28                  | 1.1        | 13.7| –   | 16,220              | 3640                 |
| Patient 5 (23)         | S. epidermidis         | Present | 11                  | 1.3        | 8.3 | –   | 28,750              | 18,470               |
| Patient 6 (14)         | Staphylococcus aureus  | Present | 6                   | 2.5        | 58.8| –   | 8,440               | 6,650                |
| Patient 7 (25)         | S. aureus             | Present | >3                  | 1.9        | 1.3 | –   | 2,630               | 820                  |
| Patient 8 (52)         | S. aureus             | Present | >3                  | 3.7        | 14.9| –   | 5,080               | 2,270                |
| Patient 9 (53)         | Negative              | Present | 11                  | 2.0        | 36  | –   | 23,590              | 19,120               |
| **Early onset sepsis** |                       |                |                      |            |     |     |                     |                      |
| Patient 10 (8)         | Negative               | Present | <1                  | 1.2        | 32.2| –   | 2,717               | 21,150               |
| Patient 11 (30)        | Negative               | Present | <1                  | 1.6        | 2.1 | 1,180| 6,580               | 1,280                |
| Patient 12 (34)        | Negative               | Present | <1                  | 2.3        | 11.7| –   | 7,950               | 4,650                |
| Patient 13 (17)        | Negative               | Present | <1                  | 1.6        | 15.2| 306 | 14,300              | 6,120                |
| Patient 14 (35)        | Negative               | Present | 2                   | 1.3        | 4.2 | –   | 9,580               | 5,440                |
| Patient 15 (36)        | Staphylococcus haemolyticus | Present | <1                     | 1.6      | 10.8| –   | 9,150               | 7,400                |
| **Early and Late onset Sepsis** |                  |                |                      |            |     |     |                     |                      |
| Patient 16 (4)         | Escherichia coli S. epidermidis | Present | <1                     | 2.7      | 37.3| –   | 35,560              | 25,420               |
| Patient 17 (37)        | S. epidermidis         | Present | <1                  | 1.3        | 111 | –   | 10,500              | 7,750                |

Dab: days after birth; CRP: C-reactive protein; WBC: white blood cell count; IL-6, interleukin 6. When clinical signs of sepsis were present, the diagnosis of sepsis was confirmed.

Sign (–) indicates no measured parameter. Patient number noted using parentheses corresponds to the patients showed in PCA graph in Figure 1.
FIGURE 1 | DNAm analysis. (A) Principal component analysis (PCA) of methylation data of control (light green), LOS (pink), EOS (light blue), and EOS plus LOS (purple) samples. (B) DNAm heatmap showing the significant top 1,000 differentially methylated CpGs between controls and neonates with sepsis, obtained with (Continued)
FIGURE 1 | limma. The methylation metric used to obtain the heatmap is the beta values scaled by the median, shown at the top left color scale (where red represents higher methylation levels, and green lower methylation levels). This displays the clustering of sepsis samples separated from control samples with the exception of one LOS sample. (C) eFORGE analysis. Enrichment analysis of regulatory element classes in different blood cell types for the top 1,000 CpG sites between septic neonates and control neonates. Cell types are shown on the horizontal axis and the significance (−log_{10} binomial p-values) is shown on the vertical axis. Each dot represents an enrichment q-value for a given cell type, colored according to the enriched regulatory element class, as shown in the legend (where yellow points correspond to enhancers and red points correspond to transcription start sites).

FIGURE 2 | Volcano plots of the different contrasts performed with mCSEA. Volcano plots show the beta-value difference in the x-axis plotted vs. −log_{10} FDR in the y-axis. Black (not significant) and green (Mean beta diff.) dots were non-significant promoters, while blue (FDR) and red (FDR and mean beta diff.) dots correspond to the significant DMRs, below the selected FDR threshold of significance set at 0.05. Those with a mean beta difference >10% are represented as red and green dots. (A) Volcano plot of the sepsis vs. control contrast, (B) LOS vs. control contrast, (C) EOS vs. control comparison, and (D) LOS vs. EOS.
and SIT1 genes (Figure 2A). Conversely, in contrast with the high number of promoters with differential hypomethylation, only 4 genes (MPO, LOC100131496, SPII, and PLEK) showed a beta-value difference above 10%.

In addition, we used the DMRcate method and identified 14,846 genomic regions by fitting DMCs spatially. The vast majority of DMRs were hypermethylated regions, and only 1,577 were hypermethylated. Furthermore, those with a mean beta difference above 10% provided 1,474 DMRs with hypomethylation and 386 DMRs with hypermethylation.

After overlapping the DMR sets obtained with both methods (mCSEA and DMRcate), 302 promoters and 108 genes were found to be hypomethylated and 143 promoters hypermethylated. Table 3 shows the promoters with the greatest beta differences (>10%) obtained with the two methods for the comparisons between neonatal sepsis and control neonates.

### Differential Methylation in EOS and LOS to Identify Distinct Molecular Responses in Both Subtypes of Neonatal Sepsis

As shown in the results above, comparisons between EOS and controls and between LOS and EOS exhibited smaller differences in DNA methylation between conditions. Therefore, we used the mCSEA method which allows discovery of regions with high sensitivity and subtle differences in DNA methylation but with consistency across a genomic region.

Among the 1,433 promoters obtained with mCSEA, 50 had a difference >10%, and some of them were associated with relevant genes involved in immunological functions (Figure 2B). Nevertheless, the comparison between EOS and controls showed differential methylation in only 44 genes and 108 promoters, in which relevant genomic regions that showed significant changes in LOS—such as S100A8, TREM1, ELANE, CD3D, and CD3G—were not present. Importantly, promoters of CSTA, MIR145, PRTN3, and ATP8B4 genes were differentially methylated in EOS as well as in LOS when compared to controls (Figure 2C).

When we compared LOS with EOS, 803 differentially methylated promoters were obtained, most of them with small differences except for 4 hypomethylated promoters, which displayed large beta differences for gene promoters of DUSP22, PM20D1, MIR10A, and MIR886 (Figure 2D).

### Table 3 | General overview of differentially methylated (hypomethylated and hypermethylated) promoters detected by both DMR detection methods (mCSEA and DMRcate) for the comparison between neonatal sepsis and control neonates, including mean beta-value difference, chromosome location, and a brief description.

| Methylation status | Gene   | Localization | Mean beta difference | Description                                                                 |
|--------------------|--------|--------------|----------------------|-----------------------------------------------------------------------------|
| Hypo-              | S100A8 | chr1         | −0.11720             | Inflammatory mediator participating in the amplification of the immune response. It has also been proposed as a mediator of immunosuppressive states by regulating myeloid-derived suppressor cells (MDSCs) |
|                    | CSTA   | chr3         | −0.11370             | Cysteine protease inhibitor (cystatin superfamily) which plays a role in epidermal development and maintenance. It is expressed in tissues participating in the first-line defense against pathogens |
|                    | ATP8B4 | chr15        | −0.11232             | Member of type IV P-type ATPases which catalyze the translocation of phospholipids in the cell membrane |
|                    | TREM1  | chr6         | −0.11815             | Cell surface receptor that stimulates the release of pro-inflammatory cytokines and chemokines, and cell surface activation molecules in neutrophils and monocytes. TREM1 amplifies inflammation and is a crucial mediator of septic shock |
|                    | CD300LB| chr17        | −0.11186             | Activating receptor of the immunoglobulin superfamily expressed on myeloid cells |
|                    | ELANE  | chr19        | −0.11067             | Serine protease involved in the extracellular matrix degradation of microorganisms through the proteolysis of elastin and other components |
|                    | CMYA5  | chr5         | −0.10973             | Cardiomyopathy-associated protein 5 |
|                    | LRG1   | chr19        | −0.10656             | Expressed during neutrophil granulocyte differentiation, involved in neutrophil degranulation |
|                    | IL10   | chr1         | −0.10504             | Anti-inflammatory cytokine involved in immunoregulation and inflammation |
|                    | MIR145 | chr5         | −0.10161             | mRNA which plays a role in the growth and division of megakaryocytes |
|                    | PRTN3  | chr19        | −0.10104             | Serine protease, paralog of neutrophil elastase (ELANE) |
| Hyper-             | CD3G   | chr11        | 0.15725              | Subunit of the TCR-CD3 complex, on the surface of T-cells |
|                    | CD3D   | chr11        | 0.15212              | Subunit of the TCR-CD3 complex, on the surface of T-cells |
|                    | LTA    | chr6         | 0.11763              | Cytokine that mediates in inflammatory, immunostimulatory, and antiviral responses |
|                    | TXK    | chr4         | 0.11473              | Tec family protein tyrosine kinase that regulates T-cell function and differentiation, and participates in Th1 cytokine production |
|                    | UBASH3A| chr21        | 0.10833              | Encodes a protein that belongs to the T-cell ubiquitin ligand (TULA) that negatively regulates T-cell signaling |
|                    | SIT1   | chr9         | 0.10786              | Negatively regulates TCR-mediated signaling in T-cells, and is involved in positive selection of T-cells |
important functions, and as a result similar GO biological processes related with immune response were obtained using both methods (Figure 3).

After the overlapping of the DMRs for genes and promoters, obtained with mCSEA and DMRcate approaches, an overrepresentation analysis (ORA) revealed the enrichment
of hypermethylated regions in T-cell activation and T-cell differentiation to be the processes with the highest significance, among other relevant GO terms (Figure 4A), which demonstrates the scarce immunoreactivity of the cells in septic neonates. Moreover, a high proportion of hypomethylated regions were enriched in neutrophil degranulation and activation involved in immune response processes, as well as in mast cell activation and response to molecules of bacterial origin.
Regarding KEGG pathways, the most relevant pathways enriched in the set of hypermethylated DMRs were T-cell receptor signaling pathway, Th17 cell differentiation, and PD-L1 expression and PD-1 checkpoint pathway, which are related with immunosuppression processes (Figure 4C).

**DISCUSSION**

Sepsis produces high mortality and morbidity and adverse long-term effects in neonates. The pathophysiology of neonatal sepsis is not yet fully understood. We propose that epigenetics is involved in the immunopathology of sepsis and can provide biomarkers for clinical management of early onset and late onset sepsis.

Neonatal immune development is complex and incompletely understood. Moreover, neonatal immune development is orchestrated by many factors including intra- and extrauterine exposure to antigens and commensal organisms, which determine the susceptibility of the newborn to sepsis.

Notably, our results reveal significant changes in the DNA methylation between septic and controls, indicating that sepsis produces epigenetic reprogramming in leukocytes. With sepsis both hyperinflammatory and immunosuppressive responses occur. Our results reinforce this idea, since methylation changes occur simultaneously in both pro- and anti-inflammatory mediators.

Upon infection, the immune response relies primarily on the innate immune system, which is not fully mature in preterm infants. Changes in DNA methylation were greater in LOS than in EOS when compared to controls. Hence, the lower methylation levels observed in the promoters of genes involved in neutrophil activation, such as ATP8B4, LRG1, TREM1, PRTN3, S100A8, ELANE, and CD177, illustrate the role of DNA methylation in innate immunity in neonatal sepsis. In addition, TREM-1, which has been proposed as an early biomarker of neonatal sepsis, is involved in the amplification of neutrophil and monocyte inflammatory responses by stimulating pro-inflammatory cytokines.

Furthermore, the hypomethylation found in the gene coding for neutrophil elastase (ELANE) and proteinase 3 (PRTN3) may alter the formation of NETs (neutrophil extracellular traps), which is an earlier mechanism used by neutrophils to fight infection.

In line with pro-inflammatory responses, previous studies revealed the involvement of CD300b in LPS-induced sepsis as well as apoptotic cell phagocytosis mediated by macrophages. As the excessive inflammatory response in sepsis entails apoptosis of lymphocytes and epithelial cells, CD300b contributes to sepsis, so the hypomethylation of the CD300b promoter found in our study correlates with previous findings. Another relevant pro-inflammatory gene is LTA (lymphotoxin alpha), which is a cytokine produced by lymphocytes. This member of the tumor necrosis factor family is associated with increased risk of sepsis in adults, so the hypermethylation we found in LTA also suggests its use as a predictive marker for risk of sepsis in neonates.

IL-10, together with IL-6 and IL-8, are initial markers with high specificity for neonatal sepsis. The upregulation of IL-10 in sepsis is concordant with the lower methylation levels we found in its promoter and may contribute to the immunosuppressive response in neonatal sepsis. In addition, the gene encoding for the inflammatory and immunosuppressive protein S100A8 (S100 calcium binding protein A8) showed low methylation. Interestingly, S100A8 is an alarmin related with immunosuppression, because it prevents the expansion of specific inflammatory monocyte populations in septic neonates.

Regarding the adaptive immune response, T-cell activation is known to be downregulated during the immunosuppressive state. Interestingly, we found that the promoters of genes involved in T-cell regulation, such as CD3D, CD3G, UBAH3A, SIT1, and TXX, were hypermethylated in neonatal sepsis compared to controls, thereby resulting in decreased expression. The CD3D and CD3G proteins are subunits of the TCR-CD3 complex (TCR-T-cell receptor). The TCR-CD3 complex is a multicomponent membrane receptor in mature T cells and in thymocytes, whose under-expression has been described in adult sepsis.

Our results reinforce this idea, since methylation changes occur simultaneously in both pro- and anti-inflammatory mediators.

Among other significant methylated genes of interest in the context of neonatal sepsis, we also found CALR, which codes for calreticulin, an endoplasmic reticulum resident protein, with functions in leukocyte migration and related with the severity of sepsis. In addition, our study further revealed the hypomethylation of MPO gene, coding for myeloperoxidase, which has previously been described as a potential marker of mortality in sepsis.

The overlapping of the DMRs for genes and promoters showed in Figure 4, obtained with mCSEA and DMRcate approaches, revealed the scarce immunoreactivity of T-cells in septic neonates. Interestingly, KEGG pathways demonstrate the enrichment of hypermethylated DMRs for T-cell receptor signaling pathway, Th17 cell differentiation, and PD-L1 expression and PD-1 checkpoint pathway, which has been related with immunosuppression processes.

Importantly, using mCSEA method we were able to identify 4 gene promoters in DUSP22, PM20D1, MIR10A, and MIR886 with significant differential DNA methylation when comparing LOS and EOS. Among these genes, DUSP22 codes for a JAK, a JNK pathway-associated phosphatase expressed in various types of human immune cells (e.g., T cells, B cells, and natural killer cells) and PD-L1 expression and PD-1 checkpoint pathway, which has been related with immunosuppression processes.

Importantly, using mCSEA method we were able to identify 4 gene promoters in DUSP22, PM20D1, MIR10A, and MIR886 with significant differential DNA methylation when comparing LOS and EOS. Among these genes, DUSP22 codes for a JAK, a JNK pathway-associated phosphatase expressed in various types of human immune cells (e.g., T cells, B cells, and natural killer cells) and PD-L1 expression and PD-1 checkpoint pathway, which has been related with immunosuppression processes.

Interestingly, a work by Khartsev et al. suggest higher values for TNF-α, IL-1β, IL-6 in LOS than in EOS, which is in agreement with the low methylation levels identified in its promoter found in our study.
agreement with the observation of higher methylation of DUSP22 in LOS than in EOS. In addition, DUSP22 downregulation correlates with severity, higher level of systemic inflammation, and poor survival in adult septic patients (54). It would be interesting to measure DUSP22 methylation in a cohort of neonatal septic patients in order to evaluate its potential as prognostic biomarkers in neonatal sepsis. Regarding MIR10A, it has been shown that miR-10a levels in PBMC at admission were significantly lower in sepsis patients compared with non-septic patients with infection, and with healthy controls (58). Moreover, miR-10a levels were found to predict 28-day mortality and negatively correlate with disease severity as well as levels for C-reactive protein, procalcitonin, and inflammatory cytokines such as IL-6, TNF-α, and MCP-1 (58). Regarding MIR886, it has been shown that miR-886-5p is increased in human monocyte-derived macrophages as a response to mycobacterial infection at 48h (59), and the isoform hsa-miR-886-3p was present at higher levels in PBMCs from critically ill patients infected with H1N1 influenza virus than PBMCs from healthy controls (60). Interestingly, miR-886-5p targets IRAK3, BAX, and TP53 transcripts (59), contributing to inhibiting apoptosis (61). In our study we found the hypomethylation of MIR886 in LOS compared to EOS, which may contribute to its upregulation, thereby inhibiting apoptosis in immune cells and setting the basis for an adaptive response in more mature immune cells. This is of special relevance because persistence of immunosuppression related to epigenetic dysregulation (6) may increase the susceptibility for future infections and increases the risk of mortality (11, 17).

Our study has some limitations, especially in the small number of newborns included in each group. Nonetheless our results importantly set the basis for further research aimed to validate our findings and provide novel biomarkers for neonatal sepsis based on DNA methylation.

CONCLUSIONS

DNAm profiles with differential methylation were observed between newborns with sepsis and control neonates in relevant genes and promoters involved in immune pathways. Our study demonstrates the potential use of DNAm to reveal relevant mechanisms underlying the inflammatory and immune dysregulation in neonatal sepsis, and particularly in EOS and LOS, which can help to clarify its physiopathology and therefore contribute to prevent life-threatening complications during neonatal sepsis.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The .idat files of the 23 samples were deposited on Gene Expression Omnibus (GEO) with the number GSE155952.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Committee from Hospital Universitario y Politécnico la Fe (Valencia, Spain) with registration number 2017/0470. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

AUTHOR CONTRIBUTIONS

JG-G, MV, SM-M, PN, and FP: conception, study design, and coordination. MV, SL-P, and IL-C: wrote the ethics committee application, present the informed consent, and collect the samples. SL-P, PN, MG, IL-C, JB-G, RO-V, and SM-M: experiment performing and data acquisition. PN, MG, and EG-L: statistical analysis. JG-G, SL-P, SM-M, MV, PN, SL-P, EG-L, and FP: drafting manuscript. All authors approved the final version of the manuscript and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All persons designated as authors qualify for authorship, and all those who qualify for authorship are listed.

FUNDING

This work was supported by AES from Spanish Institute of Health Carlos III grant numbers [AES2019, PI19/00994; PFIS grant FI18/0131] co-financed by the European Regional Development Fund (ERDF); by RETICS grant number [PN 2018-2021]; by ISCIII- Sub-Directorate General for Research Assessment and Promotion and the European Regional Development Fund (FEDER) grant number [RD16/0022] and Spanish Institute of Health Carlos III through CIBERer (Biomedical Network Research Center on Rare Diseases) grant number [ACCI2018-09] and Fundación Mutua Madrileña (AP174352020). MG was supported by the Competitiveness Programme for the Promotion of Talent and its Employability in R+D+i Torres Quevedo grant from Spanish Ministerio de Ciencia e Innovación (PTQ2019-010552). RO-V is a fellowship supported by Fundación Mutua Madrileña.

ACKNOWLEDGMENTS

The authors would like to thank Dr. Juan Sandoval and the Epigenomics Unit of the Instituto de Investigación Sanitaria La Fe for their support in performing Infinium Human DNA Methylation EPIC 850K arrays.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.622599/full#supplementary-material
REFERENCES

1. Shane AL, Sánchez PJ, Stoll BJ. Neonatal Sepsis. Lancet. (2017) 390:1770–80. doi: 10.1016/S0140-6736(17)31002-4

2. Singer M, Deutschman CS, Seymour C, Shankar-Hari M, Annane D, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). J Am Med Assoc. (2016) 315:801–10. doi: 10.1001/jama.2016.0287

3. McGovern M, Giannoni E, Kuester H, Turner MA, van den Hoogen A, Bliss JM, et al. Challenges in developing a consensus definition of neonatal sepsis. Pediatr Res. (2020) 88:14–26. doi: 10.1038/s41390-020-0785-x

4. Maddux AB, Douglass IS. Is the developmentally immature immune response in paediatric sepsis a recapitulation of immune tolerance? Immunology. (2015) 145:1–10. doi: 10.1111/imj.12454

5. Raymond SL, Stortz JA, Mira JC, Larson SD, Wynn JL, Moldawer LL. Immunological defects in neonatal sepsis and potential therapeutic approaches. Front Pediatr. (2017) 5:14. doi: 10.3389/fped.2017.00014

6. Hibbert JE, Currie A, Strunk T. Sepsis-induced immunosuppression in neonates. Front Pediatr. (2018) 6:357. doi: 10.3389/fped.2018.00357

7. Cernada M, Serna E, Bauerl C, Collado MC, Pérez-Martínez G, Vento JM. Genome-wide expression profiles in very low birth weight infants with neonatal sepsis. Pediatrics. (2014) 133:e2103–11. doi: 10.1542/peds.2013-2552

8. Zee-Vera A, Ochoa TJ. Challenges in the diagnosis and management of neonatal sepsis. J Trop Pediatr. (2015) 61:1–13. doi: 10.1093/jtpe/ftu079

9. Klinger G, Levy I, Sirota L, Boyko V, Reichman B, Lerner-L, Avendaño-Ortiz J, et al. Inflammatory cytokines and organ dysfunction associate with the aberrant DNA methylome of monocytes in sepsis. J Pediatr. (2019) 35:4767–69. doi: 10.1093/bioinformatics/btz456

10. Chen X, Oppenheim JJ. Th17 cells and Tregs: unlikely allies. J Leukoc Biol. (2014) 95:723–31. doi: 10.1189/jlb.1213633

11. Boskabadi Ha, Zakerihamidi M. Evaluate the diagnosis of neonatal sepsis by measuring interleukins: a systematic review. Pediatr Neonatol. (2018) 59:329–38. doi: 10.1016/j.pedi.2017.10.004

12. Zou R, Chang Y, Liu J, Chen M, Wang H, Huang M, et al. JNK pathway-associated phosphatase/DUSP22 suppresses CD4+ T-cell activation and Th1/Th17-cell differentiation and negatively correlates with clinical activity in inflammatory bowel disease. Front Immunol. (2017) 8:781. doi: 10.3389/fimmu.2017.00781

13. Peters TJ, Buckley MJ, Statham AL, Pidsey R, Samaras K, V Lord R, et al. De novo identification of differentially methylated regions in the human genome. Epigenetics Chromatin. (2015) 8:6. doi: 10.1186/s13072-015-0016-4

14. Breeze CE, Reynolds AP, Van Dongen J, Dunham I, Lazar J, Nephi S, et al. EFORGE v2.0: updated analysis of cell type-specific signal in epigenetic data. Bioinformatics. (2019) 35:4767–69. doi: 10.1093/bioinformatics/btz456

15. Van Der Poll T, Van De Veerdonk FL, Scicluna BP, Netea MG. The immune system's role in sepsis: understanding its complexity. Front Immunol. (2015) 6:3363–69. doi: 10.3389/fimmu.2015.00949

16. Bajcsy R, Liu Z, Kuroiwa T, Dorkin JR, et al. A method for evaluating clinical decision support systems using simulated SEF/SEF medical images. Clin Radiol. (2014) 69:329–38. doi: 10.1016/j.crad.2014.03.011

17. Ladizinsky N, Shalev J, Avidan M, et al. The role of new tools in the diagnosis and management of neonatal sepsis. Crit Care Med. (2015) 43:1251086. doi: 10.1093/sciencemag.org.1251086

18. Delano MJ, Ward PA. The immune system's role in sepsis progression, resolution, and long-term outcome. Immunol Rev. (2016) 274:330–53. doi: 10.1111/imr.12499

19. Watanabe E, Buchman TG, Hirasawa H, Zehnhauser BA. Association between lympho toxin-α (tumor necrosis factor-β) intron polymorphism and...
pre-distribution to severe sepsis is modified by gender and age. *Crit Care Med.* (2010) 38:181–93. doi: 10.1097/CCM.0b013e3181bc805d

44. Heinemann AS, Pirr S, Fehlhaber B, Mellingl J, Burgmann J, Mandy B. In neonates S100A8/S100A9 alarms prevent the expansion of a specific inflammatory monocyte population promoting septic shock. *FASEB J.* (2017) 31:1153–64. doi: 10.1096/fj.201601083R

45. Lu X, Xue L, Sun W, Ye I, Zhu Z, Mei H. Identification of key pathogenic genes of sepsis based on the gene expression omnibus database. *Mol Med Rep.* (2017) 17:3042–54. doi: 10.3892/mmr.2017.8258

46. Cazalis M-A, Lepape A, Venet F, Frager F, Mougin B, Vailin H, et al. Early and dynamic changes in gene expression in septic shock patients: a genome-wide approach. *Intensive Care Med. Exp.* (2014) 2:20. doi: 10.1186/s40635-014-0020-3

47. Ge Y, Paisek TK, Chen S, Concannon P. UBASH3A regulates the synthesis and dynamics of TCR–CD3 complexes. *J Immunol.* (2019) 203:2827–36. doi: 10.4049/jimmunol.1801138

48. Marie-Cardine A, Kirchgesner H, Bruyns E, Shevchenko A, Mann M, Autschbach F, et al. SHP2-interacting transmembrane adaptor protein (SIT), a novel disulfide-linked dimer regulating human T cell activation. *J Exp Med.* (1999) 189:1181–94. doi: 10.1084/jem.189.8.1181

49. Xu Z, Yang Y, Zhou J, Huang Y, Wang Y, Zhang Y, et al. Role of plasma calreticulin in the prediction of severity in septic patients. *Dis Markers.* (2019) 2019:8792640. doi: 10.1155/2019/8792640

50. Schrijver IT, Kemperman H, Roest M, Kesecioglu J, de Lange DW. Myeloperoxidase can differentiate between sepsis and non-infectious SIRS and predicts mortality in intensive care patients with SIRS. *Intensive Care Med Exp.* (2017) 5:43. doi: 10.1186/s40635-017-0157-y

51. Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. *Nature.* (2018) 560:382–6. doi: 10.1038/s41586-018-0392-8

52. Patil N, Guo Y, Luan L, Sherwood E. Targeting immune cell checkpoints during sepsis. *Int J Mol Sci.* (2017) 18:2413. doi: 10.3390/ijms18112413

53. Chuang H-C, Chen Y-M, Hung W-T, Li J-P, Chen D-Y, Lan J-L, et al. Downregulation of the phosphatase JAKP/DUSP22 in T cells as a potential new biomarker of systemic lupus erythematosus nephritis. *Oncotarget.* (2016) 7:57593–605. doi: 10.18632/oncotarget.11419

54. Zhao M, Huang X. Downregulation of JAKP is correlated with elevated disease risk, advanced disease severity, higher inflammation, and poor survival in sepsis. *J Clin Lab Anal.* (2019) 33:e22945. doi: 10.1002/jcla.22945

55. Mirzarahimi M, Barak M, Eslami A, Enteshari-Moghadam A. The role of interleukin-6 in the early diagnosis of sepsis in premature infants. *Pediatr Rep.* (2017) 9:7305. doi: 10.4081/pr.2017.7305

56. Krueger M, Nauck MS, Sang S, Hentschel R, Wieland H, Berner R. Cord blood levels of interleukin-6 and interleukin-8 for the immediate diagnosis of early-onset infection in premature infants. *Neonatology.* (2001) 80:118–23. doi: 10.1159/000047130

57. Khaertynov KS, Boichuk S V., Khaiboullina SF, Anokhin VA, Andreeva AA, Lombardí VC, et al. Comparative assessment of cytokine pattern in early and late onset of neonatal sepsis. *J Immunol Res.* (2017) 2017:1–8. doi: 10.1155/2017/8601063

58. Zheng G, Qiu G, Ge M, Meng J, Zhang G, Wang J, et al. miR-10a in peripheral blood mononuclear cells is a biomarker for sepsis and has anti-inflammatory function. *Mediat Inflamm.* (2020) 2020:1–10. doi: 10.1155/2020/4370983

59. Sharbati J, Lewin A, Kutz-Lohroff B, Kamal E, Einspanier R, Sharbati S. Integrated MicroRNA-mRNA-analysis of human monocyte derived macrophages upon *Mycobacterium avium* subsp. *hominisuis* Infection. *PLoS ONE.* (2011) 6:e20258. doi: 10.1371/journal.pone.0020258

60. Song H, Wang Q, Guo Y, Liu S, Song R, Gao X, et al. Microarray analysis of MicroRNA expression in peripheral blood mononuclear cells of critically ill patients with influenza A (H1N1). *BMC Infect Dis.* (2013) 13:257. doi: 10.1186/1471-2334-13-257

61. Li J-H, Xiao X, Zhang Y-N, Wang Y-M, Feng L-M, Wu Y-M, et al. MicroRNA miR-886-3p inhibits apoptosis by down-regulating Bax expression in human cervical carcinoma cells. *Gynecol Oncol.* (2011) 120:45–51. doi: 10.1016/j.ygyno.2010.09.009

Conflict of Interest: JG-G, FP, and SM-M are owners of EpiDisease's shares. JG-G and SM-M are currently the C.E.O. and C.S.O. of 1446 EpiDisease S.L., respectively. EpiDisease is a Spin-Off of the Consortium Centre for Biomedical Network Research on Rare Diseases (Spanish Institute of Health- Instituto de Salud Carlos III), the Biomedical Research Centre INCLIVA and the University of Valencia. There are no patents, products in development or marketed products associated with this research to declare.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Lorente-Pozo, Navarrete, Garzón, Lara-Cantón, Beltrán-García, Osca-Verdegal, Monã-Mollá, García-López, Vento, Pallarós and García-Giménez. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.